BPG is committed to discovery and dissemination of knowledge
Case Control Study
Copyright: ©Author(s) 2026.
World J Clin Pediatr. Jun 9, 2026; 15(2): 117283
Published online Jun 9, 2026. doi: 10.5409/wjcp.v15.i2.117283
Table 2 Comparison of the serum growth differentiation-15 levels among the study groups, mean ± SD
Serum GDF-15 (pg/mL)
Cases (n = 100)
Controls (n = 50)
P value
948.35 ± 386.29
249.48 ± 99.9
< 0.001a
Serum GDF-15 (pg/mL)Congenital heart diseases (n = 69)Rheumatic heart diseases (n = 14)Cardiomyopathy (n = 17)P valueP1P2P3
852.07 ± 376.391081.43 ± 435.281229.53 ± 166.6< 0.001a0.029a< 0.001a0.796
Serum GDF-15 (pg/mL)TOF (n = 16)PDA + VSD + ASD (n = 53)P value
1138.38 ± 249.32765.64 ± 366.74< 0.001a
Serum GDF-15 (pg/mL)Patients with heart failure (n = 50)Patients without heart failure (n = 50)P value
1170 ± 292.55726.7 ± 340.04< 0.001a


Write to the Help Desk